北京科鋭(002350.SZ):付小東成為公司實控人
格隆匯 12 月 14日丨北京科鋭(002350.SZ)公佈,近日,公司收到張新育及科鋭北方的通知,張新育及科鋭北方其他股東向秦煤運銷合計轉讓其所持科鋭北方1519.89萬元出資(佔科鋭北方註冊資本的75%)已於2020年12月11日完成工商變更登記手續,並取得由北京市海淀區市場監督管理局頒發的新營業執照。
截至目前,科鋭北方仍持有公司1.47億股無限售流通股股份,佔公司總股本的27.11%,仍為公司控股股東,秦煤運銷通過持有科鋭北方1519.89萬元出資(佔科鋭北方註冊資本的75%),從而間接持有公司1.47億股股份,佔公司總股本的27.11%。秦煤運銷的實際控制人付小東成為公司實際控制人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.